This paper is in the following e-collection/theme issue:

Statistical Methods for Surveillance and Population Health (156) Cancer Survivorship (258) Clinical Informatics (1022) Descriptive Epidemiology and Population Size Estimates (107) eHealth Service, Product, Resource Reviews (30) Health Care Quality and Health Services Research (271)

Published on in Vol 9 (2023)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/49968, first published .
Nasopharyngeal Cancer Incidence and Mortality in 185 Countries in 2020 and the Projected Burden in 2040: Population-Based Global Epidemiological Profiling

Nasopharyngeal Cancer Incidence and Mortality in 185 Countries in 2020 and the Projected Burden in 2040: Population-Based Global Epidemiological Profiling

Nasopharyngeal Cancer Incidence and Mortality in 185 Countries in 2020 and the Projected Burden in 2040: Population-Based Global Epidemiological Profiling

Authors of this article:

Yanting Zhang1 Author Orcid Image ;   Harriet Rumgay2 Author Orcid Image ;   Mengmeng Li3, 4 Author Orcid Image ;   Sumei Cao3, 4 Author Orcid Image ;   Wanqing Chen5 Author Orcid Image
Article Authors Cited by (25) Tweetations (8) Metrics

Journals

  1. Li H, Liang B, Gao X, Peng Y, Liu Q, Qiu L, Lin J. Cathepsin B-Activated PET Tracer for In Vivo Tumor Imaging. Molecular Pharmaceutics 2024;21(3):1382 View
  2. Wang R, Ke R, Yu Y, Lu G, Wu S. Addition of nimotuzumab to concurrent chemoradiotherapy after induction chemotherapy improves outcomes of patients with locally advanced nasopharyngeal carcinoma. Frontiers in Pharmacology 2024;15 View
  3. Makowska A, Weiskirchen R. Nasopharyngeal Carcinoma Cell Lines: Reliable Alternatives to Primary Nasopharyngeal Cells?. Cells 2024;13(7):559 View
  4. Chen Z, Ling J, Zhang S, Feng Y, Xie Y, Liu X, Hou T. Predicting the overall survival and progression‐free survival of nasopharyngeal carcinoma patients based on hemoglobin, albumin, and globulin ratio and classical clinicopathological parameters. Head & Neck 2024;46(10):2600 View
  5. Shen H, Zhang C, Li S, Liang Y, Lee L, Aggarwal N, Wun K, Liu J, Nadarajan S, Weng C, Ling H, Tay J, Wang D, Yao S, Hwang I, Lee Y, Chang M. Prodrug-conjugated tumor-seeking commensals for targeted cancer therapy. Nature Communications 2024;15(1) View
  6. Jiménez-Labaig P, Rullan A, Hernando-Calvo A, Llop S, Bhide S, O’Leary B, Braña I, Harrington K. A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies. Cancer Treatment Reviews 2024;128:102772 View
  7. Xiao M, Tu L, Zhou T, He Y, Li X, Zuo Q. Predictive model based on multiple immunofluorescence quantitative analysis for pathological complete response to neoadjuvant immunochemotherapy in lung squamous cell carcinoma. Frontiers in Oncology 2024;14 View
  8. Fatima K, Andleeb A, Nasreen S, Sofi M, Wani U, Rasool M, Najmi A, Qamar S, Ahmad N, Ryhan R. Induction versus Adjuvant Chemotherapy Combined with Concurrent Chemoradiation: What Is Beneficial in Locally Advanced Nasopharyngeal Carcinoma—A 5-Year Comparative Study at a Tertiary Care Center in North India. South Asian Journal of Cancer 2024 View
  9. Yu Y, Lu G, Wang R, Song Y, Wu S. Additional PD-1 inhibitor improves complete response to induction chemotherapy in locally advanced nasopharyngeal carcinoma. Frontiers in Immunology 2024;15 View
  10. Lei S, Chen L, Ji P, Li K, Li Q, Huang C, Wang G, Ma J, Guo R, Tang L. Global burdens of nasopharyngeal carcinoma in children and young adults and predictions to 2040. Oral Oncology 2024;155:106891 View
  11. Sun B, Yuan Z, Wang M, Xu L, Feng J, Chen J. The chemokine CCL14 is a potential biomarker associated with immune cell infiltration in lung adenocarcinoma. Discover Oncology 2024;15(1) View
  12. Guo L, Rao M, Yu Y, Lin Q, Wu S. The addition of nimotuzumab during concurrent chemoradiotherapy improved survival outcomes in locally advanced nasopharyngeal carcinoma patients with optimal response to induction chemotherapy. BMC Cancer 2024;24(1) View
  13. Lim E, Ong Y, Chou Y, Then C. Interconnected influences of tumour and host microbiota on treatment response and side effects in nasopharyngeal cancer. Critical Reviews in Oncology/Hematology 2024;202:104468 View
  14. Zeng F, Zhang D, Chen S, Chen R, Chen C, Huang S, Li D, Zhang X, Chen J, Mo C, Gao L, Zeng J, Xiong J, Chen Z, Bai F. Application of fecal immunochemical test in colorectal cancer screening: A community-based, cross-sectional study in average-risk individuals in Hainan. World Journal of Gastrointestinal Oncology 2024;16(8):3445 View
  15. Ashique S, Houshyari M, Islam A, Pal R, Ghazanfar S, Taghizadeh-Hesary F. The role of microbiota in nasopharyngeal cancer: Where do we stand?. Oral Oncology 2024;158:106982 View
  16. Hu L, Huang Y, Zhang J. Maintenance treatment with oral anticancer agents after first-line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis. European Archives of Oto-Rhino-Laryngology 2024 View
  17. Ho-Fun Lee V. Approaching a cure for nasopharyngeal carcinoma: how close are we from there?. The Lancet Regional Health - Western Pacific 2024;50:101186 View
  18. Zhu Y, Xue F. Comparing long-term efficacy and safety of GP versus TPF sequential chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis. BMC Cancer 2024;24(1) View
  19. Ko M, Yang K, Ahn Y, Ju S, Oh D, Kim Y, Kwon D, Park S, Lee K. Dosimetric Comparison and Selection Criteria of Intensity-Modulated Proton Therapy and Intensity-Modulated Radiation Therapy for Adaptive Re-Plan in T3-4 Nasopharynx Cancer Patients. Cancers 2024;16(19):3402 View
  20. Yi Y, Zhou B, Man T, Xu Z, Tang H, Li J, Sun Z. Resveratrol Inhibits Nasopharyngeal Carcinoma (NPC) by Targeting the MAPK Signaling Pathway. Anti-Cancer Agents in Medicinal Chemistry 2024;24(16):1207 View
  21. Chen X, Li S, Sun B. Downregulation of short‐stature homeobox protein 2 suppresses gastric cancer cell growth and stemness in vitro and in vivo via inactivating wnt/β‐catenin signaling. Drug Development Research 2024;85(7) View
  22. Krishnan M, Basappa S, Vinaya Kumar M, Sekar G. Immune checkpoint inhibition in NPC: A comprehensive review of PD-L1 overexpression and treatment responses. Oral Oncology Reports 2024;12:100680 View
  23. Guo L, Dai Y, Yu Y, Wu S. Gender-Specific Survival of Nasopharyngeal Carcinoma in Endemic and Non-Endemic Areas Based on the US SEER Database and a Chinese Single-Institutional Registry. Clinical Epidemiology 2024;Volume 16:769 View
  24. Qiu S, Chen A, Li Q, Guo L, Cai J, Xue X. Clinical Study of Tuhuanglian Liquid Wet Compress on Acute Radiation Dermatitis of Nasopharyngeal Carcinoma. Critical Reviews in Biomedical Engineering 2025;53(1):23 View
  25. Guo L, Hong J, Wang R, Chen G, Wu S. Nasopharyngeal carcinoma survival by histology in endemic and non-endemic areas. Annals of Medicine 2024;56(1) View